Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

TOLTERODINE L-TARTRATE

All products: Limited Use (codes 290)

Other products in the same Health Canada class (G04B, G04BD) — coverage varies; not interchangeable

  • Darifenacin (Enablex): limited Use 290
  • Solifenacin (Vesicare): limited Use 290
  • Trospium chloride (Trosec): limited Use 290, Not a benefit
  • Sildenafil (Revatio): not a benefit

Detrol · DIN 02239064 · 1mg · tablet

Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-20
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290 For patients with urinary frequency, urgency or urge incontinence who have: Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects. NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed. Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden. Coverage limit: LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Detrol (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Detrol · DIN 02239064 Manufacturer: Upjohn Canada ULC; listing date 1999-09-15 Health Canada: Marketed since 2023-08-30 · brand DETROL · ATC G04BD07 TOLTERODINE · form Tablet · route Oral · ingredients TOLTERODINE TARTRATE 1 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.4910 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62518 · Verify on the e-Formulary ↗ (DIN 02239064)

Source record
DIN 02239064: Detrol Raw flags: sec12=Y, sec3=Y Item: 920000318; group id 970; item number 2302; lccId 00140; manufacturer id UJC Source form: Tab; strength: 1mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.1847; ministry $0.4910 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239064 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62518
Interchangeable products
Jamp Tolterodine · DIN 02496836 · $0.4910 Mint-Tolterodine · DIN 02423308 · $0.4910
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

DARIFENACIN

· 6 products · Limited Use, codes 290 · strengths: 7.5mg, 15mg · ER Tab

SOLIFENACIN SUCCINATE

· 30 products · Limited Use, codes 290 · strengths: 5mg, 10mg · Tab

TROSPIUM CHLORIDE

· 3 products · Listed, not a benefit (1), Limited Use, codes 290 (2) · strengths: 20mg · Tab

SILDENAFIL

· 46 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 25mg, 50mg, 100mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE DETROL (tolterodine L-tartrate tablets) is indicated for: • the symptomatic management of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence, or any combination of these symptoms. (see WARNINGS AND PRECAUTIONS and DETAILED PHARMACOLOGY, Electrophysiology). Geriatrics (≥ 65 years of age): No overall differences were observed in safety between older (patients ≥ 65 years) and younger patients (patients < 65 years) on tolterodine immediate release tablets; and therefore, no dosage adjustment for elderly patients is recommended (see WARNINGS AND PRECAUTIONS, Special Populations, DETAILED PHARMACOLOGY and CLINICAL TRIALS). https://pdf.hres.ca/dpd_pm/00072287.PDF PM date: not printed or not captured Source product: DETROL; DIN 02239064; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.